BI-10773, a sodium-glucose cotransporter 2 inhibitor for the potential oral treatment of type 2 diabetes mellitus

Current Opinion in Investigational Drugs

Volumn 11, Issue 10, 2010, Pages 1182-1190

  Aires, I ^a,b   Calado, J ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BI 10773; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; REMOGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; WARFARIN;

ADD ON THERAPY; AREA UNDER THE CURVE; BODY FAT; BODY MASS; BODY WATER; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CREATININE URINE LEVEL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG URINE LEVEL; FATIGUE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; GLUCOSURIA; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POLLAKISURIA; REVIEW; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VOMITING;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; POSTPRANDIAL PERIOD; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 77957577514     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. 958498 Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R et al J MED CHEM 2008 51 5 1145-1149
2. 969174 Bristol-Myers Squibb and AstraZeneca announce expansion of worldwide collaboration to develop and commercialize dapagliflozin in Japan. Bristol-Myers Squibb Co PRESS RELEASE 2008 December 08
3. 995565 U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease. U.K. Prospective Diabetes Study Group. No authors listed DIABETES 1995 44 11 1249-1258
4. 1007584 Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M CLIN PHARMACOL THER 2009 85 5 513-519
5. 1013542 In vitro properties and in vivo effect on urinary glucose excretion of BI 10773, a novel selective SGLT2 inhibitor. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Mark M, Eickelmann P DIABETES 2009 58 Suppl 1 Abs 521-P
6. 1040823 BI 10773, a novel and selective SGLT2 inhibitor, lowers blood glucose and improves glycaemic control in diabetic rodent models. Eickelmann P, Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Mark M DIABETOLOGIA 2009 52 Suppl 1 Abs 873
7. 1042663 Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. List JF, Woo V, Morales E, Tang W, Fiedorek FT DIABETES CARE 2009 32 4 650-657
8. 1047940 FLIP switches Fas-mediated glucose signaling in human pancreatic β cells from apoptosis to cell replication. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J, Lehmann R, Bachmann F, Tasinato A, Spinas GA, Halban PA et al PROC NATL ACAD SCI USA 2002 99 12 8236-8241
9. 1048009 β-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E DIABETES 2002 51 1 66-72
10. 1048568 Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D et al N ENGL J MED 2008 358 24 2560-2572
11. +/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. Kanai Y, Lee WS, You G, Brown D, Hediger MA J CLIN INVEST 1994 93 1 397-404
12. 1048574 Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. Rossetti L, Smith D, Shulman GI, Papachristou D, Defronzo RA J CLIN INVEST 1987 79 5 1510-1515
13. 1048576 Molecular analysis of the SGLT2 gene in patients with renal glucosuria. Santer R, Kinner M, Lassen CL, Schneppenheim R, Eggert P, Bald M, Brodehl J, Daschner M, Ehrich JH, Kemper M, Li Volti S et al J AM SOC NEPHROL 2003 14 11 2873-2882
14. 1048578 Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting. Calado J, Loeffler J, Sakallioglu O, Gok F, Lhotta K, Barata J, Rueff J KIDNEY INT 2006 69 5 852-855
15. +-glucose cotransporters. Wright EM AM J PHYSIOL - RENAL PHYSIOL 2001 280 1 F10-F18
16. 1048582 Phlorizin: A review. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J DIABETES-METAB RES REV 2005 21 1 31-38
17. 1048583 Characterization of monocarboxylate transport in human kidney HK-2 cells. Wang Q, Lu Y, Yuan M, Darling IM, Repasky EA, Morris ME MOL PHARMACEUTICS 2006 3 6 675-685
18. 1048617 Twenty-one additional cases of familial renal glucosuria: Absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A, Scharf M, Tasic V, Greil J, Brinkert F, Kemper MJ et al NEPHROL DIAL TRANSPLANT 2008 23 12 3874-3879
19. 1048724 IDF diabetes atlas. International Diabetes Federation INTERNET SITE 2009 4th edition October
20. 1049535 Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr et al N ENGL J MED 2008 358 24 2545-2559
21. 1059817 Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Calado J IDRUGS 2009 12 12 785-798
22. 1108971 Weight loss induced by the potent and selective SGLT2 inhibitor, BI 10773, is due to body fat reduction. Studies in dietary-induced obese rats. Grempler R, Thomas L, Klein T, Mark M, Jackson H, Cheetham S, Eickelmann P DIABETES 2010 59 Suppl 1 Abs 1793-P
23. 1109343 Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, induces dose-dependent urinary glucose excretion in healthy subjects. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg PL DIABETES 2010 59 Suppl 1 Abs 76-OR
24. 1109344 Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes (T2D) on metformin. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W DIABETES 2010 59 Suppl 1 Abs 77-OR
25. 1109366 Canagliflozin improves glycemic control in subjects with type 2 diabetes (T2D) not optimally controlled on stable doses of insulin. Schwartz S, Morrow L, Hompesch M, Devineni D, Skee D, Vandebosch A, Murphy J, Pfeifer M DIABETES 2010 59 Suppl 1 Abs 564-P
26. 1109377 Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y et al DIABETES 2010 59 Suppl 1 Abs 568-P
27. 1109380 Safety, tolerability, pharmacokinetics and pharmaco-dynamics of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), in healthy volunteers. Port A, Macha S, Seman L, Nehmiz G, Simons G, Koegel A, Harder D, Ren B, Iovino M, Pinnetti S, Dugi KA DIABETES 2010 59 Suppl 1 Abs 569-P
28. 1109386 Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with type 2 diabetes. Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, Heise T, Dugi KA DIABETES 2010 59 Suppl 1 Abs 571-P
29. 1109447 Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BI 10773, a sodium-glucose co-transporter inhibitor (SGLT2), in Japanese healthy volunteers. Koiwai K, Seman L, Yamamura N, Macha S, Taniguchi A, Negishi T, Sesoko S, Dugi KA DIABETES 2010 59 Suppl 1 Abs 2175-PO
30. 1109452 BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), does not alter the pharmacokinetics of metformin following multiple oral administrations in healthy volunteers. Macha S, Port A, Dieterich S, Mattheus M, Peylo W, Wu J, Taub ME, Pinnetti S, Seman L, Woerle H-J DIABETES 2010 59 Suppl 1 Abs 2112-PO
31. 1109454 BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Woerle H-J DIABETES 2010 59 Suppl 1 Abs 629-P
32. 1110920 Johnson & Johnson Pharmaceutical Research & Development reports phase 2b clinical trial results evaluating canagliflozin to treat type 2 diabetes. Johnson & Johnson PRESS RELEASE 2010 June 26
33. 1111222 Boehringer Ingelheim announces pivotal phase III data showing linagliptin reduced blood sugar compared to placebo in people with type 2 diabetes. Boehringer Ingelheim Pharmaceuticals Inc PRESS RELEASE 2010 June 28
34. 1120404 NCT01164501: Efficacy and safety of BI 10773 in patients with type 2 diabetes and renal impairment. Boehringer Ingelheim Corp CLINICALTRIALS.GOV 2010
35. 1124797 Sodium glucose co-transporter 2 inhibitors: Blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Jabbour SA, Goldstein BJ INT J CLIN PRACT 2008 62 8 1279-1284
36. 1124804 Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B DIABETES CARE 2009 32 1 193-203
37. 1124808 Diabetes. World Health Organization COMPANY WORLD WIDE WEB SITE 2009 November Fact Sheet No 312
38. 1124810 SGLT2 mediates glucose reabsorption in the early proximal tubule. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, Thomson SC, Koepsell H, Rieg T J AM SOC NEPHROL 2010 July 08 DOI:10.1681/ASN.2010030246
39. 1124811 SGLT2 inhibition - A novel strategy for diabetes treatment. Chao EC, Henry RR NAT REV DRUG DISCOV 2010 9 7 551-559
40. 1125053 R&D pipeline. Boehringer Ingelheim Corp COMPANY WORLD WIDE WEB SITE 2010 August 18
41. 1127637 Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group LANCET 1998 352 9131 837-853